article thumbnail

IISc researchers find picolinic acid’s broad-spectrum antiviral abilities, scouts for partners in pharma companies

AuroBlog - Aurous Healthcare Clinical Trials blog

Researchers at the Indian Institute of Science (IISc) have found that picolinic acid, a natural compound produced by mammalian cells, can block several disease-causing viruses such as SARS-CoV-2 and influenza A viruses. The Institute is now looking for partners in pharma companies to pursue further clinical development of the findings.

article thumbnail

Thrust on R&D to develop better medicines & demand for technologies driven by AI transforming patient care

AuroBlog - Aurous Healthcare Clinical Trials blog

The pharma companies’ thrust on R&D to develop better medicines and the demand in hospitals for advanced medical technologies driven by artificial intelligence, remote patient monitoring and wearables are transforming patient care.

Medicine 151
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The largest pharma company in Europe calls for interoperability

pharmaphorum

Data is readily shared and leveraged for decision-makers to gain insight that can help clinical research. The first focuses on the patient journey through patient partnerships – spotting areas of challenge for specific patients and developing partnerships with different stakeholders outside Roche to improve upon the patient journey.

article thumbnail

3 Barriers Between Patients and Clinical Research

Find Me Cure

As part of our patient advocacy efforts, at FindMeCure we are dedicated to creating a bridge between patients and the world of clinical research. This includes spreading clinical trial awareness, connecting patients to the trials they are interested in but also speaking up about the issues in the clinical research industry. .

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

Pharma R&D teams are solving this problem by leveraging the power of artificial intelligence (AI) in clinical trials to save time and money. Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Food and Drug Administration approval.

article thumbnail

Deep Dive: Research and Development

pharmaphorum

We take a look at efforts from charities, the government and digital innovators to boost awareness of rare conditions among GPs and make the clinical pathway smoother for patients. Inside the UK’s leading efforts to restart clinical research. Centessa’s founder on the new company’s unique R&D model.

article thumbnail

Drug development and working with specialised Rare Disease networks

pharmaphorum

During the course of the webinar, Keefer explained how specialty sites, with deep knowledge on one or certain groups of Rare Diseases, are crucial for further progress in drug development to progress the number of treatments available to Rare Disease patients and to provide support to those individuals. The potential to leverage genomic data.